Join us on March 7 for our Educated Patient Summit on Breast Cancer taking place in Miami, FL! 

×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Events
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Articles

Katie Kosko
From a weight loss drug’s possible cancer risk to a shocking cancer revelation in the death of ESPN reporter Edward Aschoff, here’s what is making headlines in the cancer space this week.
Kristie L. Kahl
How providers communicate medical bills to payers and patients, mandated by the US Centers for Medicare & Medicaid Services, still did not help patients and health care professionals in understanding differences in cost.
Katie Kosko
With many targeted treatment options for patients with CLL to use upfront, the question arises as to which one is best for the individual.
Kristie L. Kahl
A brief, multimodal psychosocial intervention for caregivers of patients undergoing hematopoietic stem cell transplantation could improve their quality of life, caregiving burden and anxiety and depression symptoms.
Kristie L. Kahl
In a first-of-its-kind study, researchers have found an increase in alcohol consumption among cancer survivors that warrants further study and possible alcohol consumption screenings prior to treatment.  
 
Kristie L. Kahl
Researchers from Roswell Park Comprehensive Cancer Center found that the use of supplements, besides a multivitamin, while patients were being treated with chemotherapy increased their risk for breast cancer recurrence or death.
Conor Killmurray
Despite differences in tumors, the addition of CDK 4/6 inhibitors to endocrine therapy showed a benefit in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer compared with endocrine therapy alone.
 
Jessica Skarzynski
The three-drug combination of Perjeta and Herceptin with Gemzar shows improved progression-free survival in patients with metastatic breast cancer to advance to a phase 3 trial.
Kristie L. Kahl
Findings from a recent study supported further evaluation of comparing anti–PD-1 to anti–PD-L1 therapy to help determine treatment options for patients with cancer.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×